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Abstract
Background: Despite moderate heritability estimates for depression-related
phenotypes, few robust genetic predictors have been identiﬁed. Potential expla-
nations for this discrepancy include the use of phenotypic measures taken from
a single time point, rather than integrating information over longer time peri-
ods via multiple assessments, and the possibility that genetic risk is shaped by
multiple loci with small effects. Methods: We developed a 14-year long-term
average depression measure based on 14 years of follow-up in the Nurses’
Health Study (NHS; N = 6989 women). We estimated polygenic scores (PS)
with internal whole-genome scoring (NHS-GWAS-PS). We also constructed PS
by applying two external PS weighting algorithms from independent samples,
one previously shown to predict depression (GAIN-MDD-PS) and another
from the largest genome-wide analysis currently available (PGC-MDD-PS). We
assessed the association of all three PS with our long-term average depression
phenotype using linear, logistic, and quantile regressions. Results: In this study,
the three PS approaches explained at most 0.2% of variance in the long-term
average phenotype. Quantile regressions indicated PS had larger impacts at
higher quantiles of depressive symptoms. Quantile regression coefﬁcients at the
75th percentile were at least 40% larger than at the 25th percentile in all three
polygenic scoring algorithms. The interquartile range comparison suggested the
effects of PS signiﬁcantly differed at the 25th and 75th percentiles of the long-
term depressive phenotype for the PGC-MDD-PS (P = 0.03), and this differ-
ence also reached borderline statistical signiﬁcance for the GAIN-MDD-PS
(P = 0.05). Conclusions: Integrating multiple phenotype assessments spanning
14 years and applying different polygenic scoring approaches did not substan-
tially improve genetic prediction of depression. Quantile regressions suggested
the effects of PS may be largest at high quantiles of depressive symptom scores,
presumably among people with additional, unobserved sources of vulnerability
to depression.
Introduction
Depression is a complex disorder adversely affecting
millions of individuals, with enormous social and eco-
nomic costs (WHO 2001). The World Health Organiza-
tion has predicted depression will be the second leading
cause of disability worldwide by 2020 (Murray and Lopez
1996). Despite its public health importance, the biological
mechanisms underlying the depression etiology remain
uncertain.
Studies suggest that genetic factors play an important
role in depression (Duffy et al. 2000), with a meta-ana-
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provided the original work is properly cited.lyzed heritability estimate from twin studies of 37% (95%
conﬁdence interval [CI], 31–43%) (Sullivan et al. 2000).
However, it has been challenging to replicate previously
identiﬁed candidate gene underlying susceptibility to
depression (Lopez-Leon et al. 2008) or explain substantial
variance in the phenotype. Genome-wide association
studies (GWAS) have been unsuccessful in identifying sig-
niﬁcant individual genetic variants either (Sullivan et al.
2009; Lewis et al. 2010; Muglia et al. 2010; Shi et al.
2011; Shyn et al. 2011; Wray et al. 2012; Hek et al. 2013;
Ripke et al. 2013). These negative ﬁndings have led to
speculation that depression is particularly heterogeneous
both clinically and etiologically, which could dramatically
reduce statistical power to identify causal loci (Craddock
et al. 2008). In addition, it is often hypothesized that for
complex disorders including major depressive disorders,
each individual risk allele only has low contribution, with
odds ratio typically in the region of 1.05–1.2 (Mitchell
2012). Statistical power may be improved by increasing
sample size, which is not always feasible; by improving
precision of phenotype measurement; or by combining
information from multiple loci such as creating polygenic
scores (PS) or taking into account interactions between
genes or loci, which may effectively increase the magni-
tude of the genetic effects.
Measurement has proven particularly challenging for
depression-related phenotypes. Psychiatric research
emphasizes distinctions between categorical diagnoses
(binary phenotypes) and dimensional symptom measures
(continuous phenotypes) (Maes et al. 1992; Prisciandaro
and Roberts 2009). Because categorical diagnoses better
distinguish individuals with true psychopathology, genetic
determinants might be easier to identify when contrasting
diagnosed cases to healthy controls. However, if the herita-
bility reﬂects the independent inﬂuence of many genes with
small effects, the phenotype is likely to be continuously
distributed and more closely related to symptom-based
measures. If so, using a binary outcome measure dichoto-
mizing a continuous phenotype reduces statistical power
compared to using a dimensional quantitative measure
with the same sample size (Helzer et al. 2006; Kraemer
2007), In general, diagnostic and symptom-based measures
are highly but not perfectly correlated (Radloff 1977).
A second challenge in measuring depression phenotypes
is appropriately deﬁning the time period of assessment.
Genetic risks are carried throughout life, but the pheno-
type manifest at any given moment reﬂects both stable
genetic contributions and ﬂuctuating, transient contextual
inﬂuences. These temporary variations reduce statistical
power to detect genotype–phenotype associations (assum-
ing transient contextual inﬂuences are independent of
genetics). Depression phenotypes in genetic association
studies are often assessed at a single time point when
symptom measures are used. A registry-based twin study of
depression suggested ongoing depression is more heritable
than mild or nonrecurring depression using the diagnostic
assessment Diagnostic and Statistical Manual of Mental
Disorders, Third Edition (DSM-III) (Lyons et al. 1998).
Integrating information across repeated assessments over
time should reduce nongenetic variability in the phenotype
and increase power to detect genetic determinants.
Combining information on multiple genetic determi-
nants via polygenic scoring is another promising approach
for explaining variance in complex phenotypes. PS com-
bine information on many genetic variants, each presumed
to have small effects, to predict phenotypes (Purcell et al.
2009). One application of PS combines information on
candidate genes previously identiﬁed in the scientiﬁc litera-
ture. This pool is likely enriched with true causal loci,
improving overall capacity to predict the phenotype. An
alternative PS approach uses genome-wide data, adopting
an agnostic prior regarding which alleles are causal and
using more liberal P-value thresholds for selecting predic-
tive polymorphisms compared to conventional criterion
for genome-wide signiﬁcance tests (Purcell et al. 2009).
For some outcomes, it explained substantially more vari-
ance in the phenotype than scores limited to conﬁrmed
genotypes (Evans et al. 2009; Purcell et al. 2009). Demir-
kan et al. (2011) adopted this approach using the Genetic
Association Information Network—Major Depressive Dis-
order (GAIN-MDD) sample to develop a genome-wide PS
that explained up to 1% of the variance in depression.
We aimed to estimate the percentage of variance in a
long-term average depression phenotype among partici-
pants in the Nurses’ Health Study (NHS) that could be
explained by PS using a genome-wide scan in NHS
(NHS-GWAS-PS) or two external PS using weights
derived by Demirkan et al. (GAIN-MDD-PS) or from the
Psychiatric GWAS Consortium—Major Depressive Disor-
der (PGC-MDD-PS). We also brieﬂy considered variance
explained by a PS using candidate genes. On the basis of
prior results from Demirkan’s study, we anticipated that
the PS could explain approximately 1% of the variance in
the depression phenotype.
Material and Methods
Study participants
The NHS is a prospective cohort study of 121,700 U.S.
female registered nurses aged 30–55 years at enrollment
in 1976. Since then, self-administered questionnaires on
medical history and lifestyle characteristics have been
collected biennially. A subcohort of 32,826 women
donated blood samples during 1989–1990. DNA was
extracted from white blood cells using the QIAmpTM
ª 2014 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. 299
S.-C. Chang et al. Polygenic Scores of Depressive Symptoms(Qiagen Inc., Chatsworth, CA) blood protocol and all
samples were processed in the same laboratory. In the
current analyses, we restricted to genetically deﬁned unre-
lated white individuals with information on depression
and genome-wide scan data available from four indepen-
dent GWAS nested in NHS that passed quality control
(QC) procedures (ﬁnal analytic N = 6989). Details
regarding study design and genotyping QC for each
GWAS were reported elsewhere (Cornelis et al. 2011) and
are summarized in Appendix 1 and Tables S2 and S3.
Phenotype
Different assessments of depressive disorder or symptoms
were collected in successive questionnaire cycles from
1992 to 2006 (Table S1), including standard symptom
measures (e.g., CES-D [Center for Epidemiologic Studies
Depression Scale]) and reports of antidepressant use or
doctor-diagnosed depression. To combine information on
depression across multiple sources of information over
14 years of follow-up, we derived a standardized compos-
ite depression score for each questionnaire cycle. We
scaled depression measures at each wave to the Geriatric
Depression Scale (GDS) administered in 2008, a depres-
sion symptom screening tool well-validated in the elderly
(Sheikh and Yesavage 1986; Sharp and Lipsky 2002). We
then used these scores to derive a 14-year long-term
depression score representing average depression scores
across all available questionnaire cycles through 2006 (up
to seven waves). This phenotype captures more accurately
both level and chronicity of depressive experience over
time. More detailed description of the derivation of this
measure is provided in Appendix 2.
To closely parallel previous study in GAIN-MDD by
Demirkan et al. (2011), we also considered a dichotomized
phenotype with the 14-year long-term depression score
when applying GAIN-MDD-PS. To determine an appropri-
ate cut-point, we dichotomized at the 89th percentile,
which best corresponded to the cut-point of the CESD-10
symptom measure of depression (CESD-10 score ≥10) that
is known to have optimal sensitivity and speciﬁcity for a
major depressive disorder diagnosis (Andresen et al. 1994).
A secondary analysis was also performed, comparing the
long-term average depression score of individuals in the
extremes: the lowest quartile versus the top 11th percentile.
In addition, we conducted another GWAS agnostic PS
analysis using a second training set, a nine-GWAS-sample
meta-analysis (which includes the GAIN sample) from
the Psychiatric Genomics Consortium (PGC), which has
been pruned to remove single-nucleotide polymorphisms
(SNPs) in high linkage disequilibrium, and applied the
weights and P-values in the PGC training set to the NHS
samples. Similar to the procedure above, we ﬁrst ﬁt the
continuous long-term composite depression score, then
the dichotomous phenotype because the depression was
originally analyzed as a dichotomous outcome in the
PGC study.
Genotyping and imputation
Exact QC protocols varied slightly by sample set (Tables
S2 and S3). Individuals with genotyping completion or
SNPs with call rates below 90% were excluded. Analyses
based on principal components (Price et al. 2006) were
conducted to assess race; any self-reported “white” sam-
ples that had substantial similarity to non-European refer-
ence samples were excluded. After QC, each study
imputed to ~2.5 million autosomal SNPs with NCBI
build 36 of Phase II HapMap CEU data (release 22) as
the reference panel using MaCH (Li et al. 2010) to
account for the different genotyping platforms and the
SNPs that failed to meet the QC criteria.
Statistical analyses
Validation of the long-term average depression
phenotype
We assessed construct validity by examining the associa-
tion between the 14-year depression measure and estab-
lished correlates of depression available in our sample:
cigarette smoking (pack-years), physical activity (Mets per
week), household characteristics, and phobic anxiety scale.
We expected depression to be associated with greater like-
lihood of smoking, less physical activity, lower occupa-
tional and socioeconomic status, and higher degree of
phobic anxiety. Details are described in Appendix 2.
Traditional GWAS
Genome-wide association analyses were ﬁrst conducted
separately for each NHS GWA substudies. A linear regres-
sion (using ProbABEL; Aulchenko et al. 2010) was per-
formed on the long-term average depression score
assuming additive genetic model, adjusting for age, disease
status, and the top three or four principal components-
derived eigenvectors to address residual population strati-
ﬁcation (depending on the sample, as detailed in the Table
S2). SNPs with minor allele frequency less than 2% or
imputation quality of R
2 less than 0.5 were excluded on a
per-substudy basis. Meta-analysis using the METAL pro-
gram was performed for each SNP across four NHS GWA
substudies, combining allelic effects with inverse variance
weighting (Willer et al. 2010). We used a genome-wide
signiﬁcance threshold P < 5 9 10
 8. Our sample provides
80% power to detect a genetic effect size of 0.1
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2 of 0.006) with minor allele fre-
quency of 0.15, under an additive genetic model.
Agnostic genome-wide polygenic scoring in NHS
(NHS-GWAS-PS)
Genome-wide PS based on agnostic priors can provide a
genetic risk score even when few of the causal genetic loci
have been consistently identiﬁed in the literature. Follow-
ing previously established methods, we ﬁrst restricted to
1,584,339 SNPs with high imputation quality (R
2 > 0.95)
that were available across all four NHS GWA substudies.
We next used the PLINK pruning procedure (200-SNP
sliding window, pairwise r
2 threshold of 0.25, and succes-
sive shift forward by ﬁve SNPs) to remove redundant
SNPs, leaving a total of 97,883 independent SNPs.
Next, we performed a cross-validation procedure to
obtain an unbiased estimate of the prediction performance.
In the PS calculations, each time we used three of the four
NHS GWA substudies as the “training” set to construct a
polygenic risk score, which was then tested in the one
remaining subsample (“testing” set). The procedure was
conducted in three steps: (1) SNP-depression associations
(beta weights) were ﬁrst extracted from each of the three
substudies in the training set. For each SNP, beta weights
and P-values were meta-analyzed across the three substud-
ies in the training set with GWAMA using inverse variance
weights (Magi and Morris 2010); (2) the PS for each
woman in the testing set was calculated as the sum of the
number of risk alleles she carried at each locus meeting the
selected P-value threshold, weighted by the meta-analyzed
beta weight from the training set; and (3) we considered
nine prespeciﬁed P-value thresholds in the training set for
selecting SNPs to be included, ranging from 10
 5 to 0.5
(Ptraining). Alternatively, we also examined Ptraining thresh-
olds with nonoverlapping ranges (10
 5 < P < 10
 4 to
0.4 < P < 0.5) to assess whether any of these ﬁner thresh-
old groups explained more variance in depression. These
PS were calculated using PLINK’s SNP scoring routine.
The cross-validation procedure was repeated four times,
rotating the testing set each time (a “leave-one-out” proce-
dure).
Genome-wide polygenic scoring from two
external studies—GAIN-MDD (GAIN-MDD-PS) and
PGC-MDD (PGC-MDD-PS)
In addition, we attempted to replicate the published ﬁnd-
ing by Demirkan et al. (2011). Through personal commu-
nication, Demirkan and colleagues provided the precise
beta weights and P-values derived from their discovery set
to facilitate replication in our cohorts. We also sought
replication using data from another nine-study
meta-analysis, which has been recently published (Ripke
et al. 2013). We again considered the same nine P-value
thresholds described above for selecting SNPs to be
included in the PS calculation. The PS analysis was indi-
vidually performed in each of the four NHS substudies
and was meta-analyzed in the end.
Candidate gene polygenic scoring in NHS
(candidate-PS)
Some investigators have suggested that the candidate gene
approach is less likely to yield true causal loci, with most
positive results arising by chance. In that case, a candidate
gene approach to PS may exacerbate the difﬁculty of such
efforts. However, given the signiﬁcant literature on candi-
date genes, the ongoing controversies regarding which
genes matter, and the substantial research attention they
have received, the candidate gene polygenic scoring in
NHS was also conducted and is described in detail in the
Data S1. Brieﬂy, to develop an informed candidate-PS, we
selected 17 candidate genes with at least two positive
prior reports of involvement in depression on the Pub-
Med via the HuGE Navigator (Yu et al. 2008) as of May
2011. Ultimately 96 independent SNPs were reserved for
analysis, and each candidate gene was represented by at
least one SNP. We used the same cross-validation proce-
dure to obtain an unbiased estimate of the prediction
performance as described above.
Analyses of associations between PS and
depression phenotypes
Assessments of the association between PS and depression
phenotype were performed in R with linear (for continuous
outcome) or logistic (for dichotomized outcome) regres-
sions. Covariates included in all PS analyses were the same
as in the SNP GWAS analysis: age, case–control status in
each original GWAS, and the three or four eigenvectors.
We further performed quantile regression models in the
best prediction model of each approach deﬁned by the sig-
niﬁcance level (NHS-GWAS-PS: P < 0.2; GAIN-MDD-PS:
P < 0.001; and PGC-MDD-PS: P < 0.2) to assess whether
the effects of PS were larger at high levels of depression
scores. Unlike linear regression models, which assess
whether the mean value of the phenotype differs by PS level
(the mean model), quantile regression models assess
whether a speciﬁc percentile, for example, the median,
differs by PS. Quantile regression was performed in the
Statistical Analysis Systems software package, version 9.3
(SAS Institute, Inc., Cary, NC). Coefﬁcients for each decile
in each of the four GWA substudies were estimated and
then meta-analyzed (with inverse variance weighting). We
bootstrapped (5000 replications) to test the association
ª 2014 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. 301
S.-C. Chang et al. Polygenic Scores of Depressive Symptomsbetween each of the three PS approaches and the interquar-
tile range for the depression measure. A P-value <0.05 was
considered a signiﬁcant association with depression scores
in quantile regressions.
Results
Initial analyses
The 14-year long-term average depression score of 6989
women in the study had a mean of 1.83 with standard
deviation (SD) of 0.65, consistent with that in the full
NHS cohort. The analytic sample did not appreciably dif-
fer from the larger cohort across a range of demographic
and other sample attributes (Table 1).
The Cronbach’s alpha for the seven-wave depression
score was 0.83, suggesting these depression assessments
measure a uniﬁed underlying attribute. In the full NHS
cohort (N = 106,020), the long-term average depression
score was signiﬁcantly positively associated with cigarette
smoking and negatively associated with physical activity
(both P’s for trend <0.0001). The association between BMI
and depression score was U-shaped (P < 0.0001), such
that both underweight and overweight women had higher
depression scores than normal-weight women (Fig. 1).
Meta-analyzed genome-wide SNP
associations
The genomic inﬂation factor (lambda) for each substudy
ranged between 1.00 and 1.01. The QQ-plot (Fig. 2) indi-
cated good adherence of observed meta-analyzed P-values
to the line of expectance, suggesting little evidence of
systematic genotyping error. No individual SNPs reached
the conventional genome-wide signiﬁcance threshold of
5 9 10
 8 for the association with long-term average
depression score (Fig. 3). The SNP with the lowest P-
value was rs6763048 (P = 8.42 9 10
 7), mapping to an
intron of SCN5A on chromosome 3. A total of 14 SNPs
had P-values <1 9 10
 5, corresponding to eight indepen-
dent SNPs (r
2 < 0.05 in 500 kb) (Table 2).
NHS-GWAS-PS analyses
The genome-wide PS similarly explained a small fraction
of variance in the long-term average depression score
(Table 3). Using the most liberal threshold of P < 0.5 to
select SNPs in the training set, the genome-wide PS was
associated with the depression score in the testing set
(P = 0.004), but explained only 0.1% of the variance. The
maximum percentage of variance explained was achieved
with slightly more conservative P-value thresholds for
SNP selection (at P < 0.3), in which the genome-wide PS
explained 0.2% of the variance (P = 0.003). When
restricted to nonoverlapping Ptraining threshold ranges, the
SNPs with the most signiﬁcant association were those
with Ptraining between 0.1 and 0.2; this group alone com-
prised nearly 9900 SNPs, but explained 0.1% of pheno-
type variation (Table 3).
GAIN-MDD-PS and PGC-MDD-PS analyses
Regardless of the P-value threshold chosen, the GAIN-
MDD-PS was not signiﬁcantly associated with either the
continuous or dichotomized depression phenotype in the
NHS sample (Table 4). The maximal proportion
explained by genome-wide PS comparing women at the
extremes of the phenotype was higher than that in the full
Table 1. Characteristics of NHS full sample versus genetic study par-
ticipants.
Characteristics
Full NHS
sample
Genotyped
sample
Sample size 121,701 6989
Age in 1992, mean (SD) 59.03 (7.28) 60.19 (6.72)
BMI in 1992, mean (SD) 26.22 (5.12) 26.70 (5.38)
Pack-year smoking in 1992,
mean (SD)
13.54 (19.76) 13.26 (19.68)
Total activity in 1992 (Mets/week),
mean (SD)
18.85 (23.18) 19.12 (21.74)
Age at blood draw, mean (SD) — 57.79 (6.76)
Self-described Caucasian, N (%) 98,376 (94.5) 6797 (97.46)
Marital status in 1992, N (%)
Married 72,454 (81.24) 5677 (82.78)
Widowed 9289 (10.42) 737 (10.75)
Divorced/separated 7416 (8.32) 439 (6.4)
Education, N (%)
RN 62,673 (70.49) 4805 (70.21)
Bachelor degree 17,675 (19.88) 1369 (20.0)
Master degree 7726 (8.69) 609 (8.9)
Doctoral degree 834 (0.94) 61 (0.89)
Husband’s highest education level, N (%)
<High school graduate 4743 (6.34) 337 (5.66)
High school graduate 29,868 (39.92) 2408 (40.44)
College graduate 21,974 (29.37) 1686 (28.31)
Graduate school 18,242 (24.38) 1524 (25.59)
Father’s occupation when participants were 16 years old, N (%)
Blue collar 56,676 (51.66) 3071 (49.03)
White collar 42,788 (39.0) 2490 (39.76)
Farmer 10,248 (9.34) 702 (11.21)
14-year average depression score,
mean (SD)
1.84 (0.62) 1.83 (0.65)
Missing 14-year average depression
score, N
15,679 0
CESD-10 score, mean (SD) 5.72 (4.15) 5.76 (4.11)
Missing CESD-10 score, N 47,804 1093
CESD-10 ≥10, % 12.23 11.89
NHS, Nurses’ Health Study; CESD, Center for Epidemiologic Studies
Depression Scale—10 items.
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signiﬁcant, likely due to the reduction in sample size
when using only individuals with extreme values of the
phenotype (n = 2920) (data not shown).
When applying the agnostic PS from a nine-study meta-
analysis of PGC-MDD, the genome-wide risk scores derived
from SNPs with less stringent Ptraining threshold were signif-
icantly associated with the continuous long-term depressive
score, but they only explained at most 0.1% of variance in
phenotype. The Nagelkerke’s R
2 was also at most 0.1%
when the depression phenotype was modeled dichoto-
mously without the statistical signiﬁcance (Table 5).
Candidate-PS analyses
Three individual SNPs (rs36011, rs1417584, and
rs6917735) showed nominally signiﬁcant associations at a
threshold of 0.05, but none remained signiﬁcant after
Bonferroni correction. Overall, the candidate-PS explained
a small fraction of the variance in the long-term average
depression scores in the NHS leave-one-out meta-analysis
(see Data S1).
Quantile regression analyses
The quantile regression suggested a modest increase in PS
effect on depression score in higher quantiles than in
lower quantiles (Fig. 4). The pseudo-R
2 increased more
than 40% in the 75th percentile quantile regression model
compared to that in the 25th percentile model in all three
PS approaches. The interquartile range comparison sug-
gested the effects of PS signiﬁcantly differed at the 25th
and 75th percentiles of the long-term depressive pheno-
type for the PGC-MDD-PS (P = 0.03) (pseudo R
2 chan-
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Figure 1. Distributions of behaviors and BMI in relation to the 14-year long-term average composite depression phenotype in the full NHS cohort
(N = 106,020). BMI, body mass index; NHS, Nurses’ Health Study.
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percentile), and this difference was at borderline statistical
signiﬁcance for the GAIN-MDD-PS (P = 0.05). The result
of candidate gene polygenic scoring could be found in the
Table S5.
Discussion
In this sample of 6989 women, we did not identify any
SNPs signiﬁcantly associated with a 14-year average
composite depression phenotype using either candidate
gene-based or conventional GWAS analyses. With the two
approaches that developed PS (NHS-GWAS-PS and PGC-
MDD-PS), we achieved nominal statistical signiﬁcance,
but never explained more than 0.2% of the phenotypic
variance. While the PS analyses indicated that SNPs with
P-values above conventional signiﬁcance thresholds may
contribute to the association, the proportion of variance
explained was much smaller than that reported in a prior
study (0.2% vs. 1%) (Demirkan et al. 2011). Further-
more, the GAIN-MDD-PS did not predict depression in
our mean model analyses. The quantile regression results
suggested modestly larger effects of PS on high- versus
low- depression quantiles, but even at high depression
quantiles (e.g., 75% percentile), the PS explained at most
0.3% of phenotype variance.
Our ﬁndings are in line with the literature in which no
locus surpassed genome-wide signiﬁcance in relation to
depression (Sullivan et al. 2009; Lewis et al. 2010; Muglia
et al. 2010; Shi et al. 2011; Shyn et al. 2011; Wray et al.
2012; Hek et al. 2013; Ripke et al. 2013). Of note is that
in a largest GWAS of psychiatric illness to date (with N
over 60,000), the PGC Cross-Disorder Group identiﬁed
SNPs at four loci that were signiﬁcantly associated with a
cross-disorder phenotype as identiﬁed by meta-analyzing
across ﬁve childhood-onset and adult-onset psychiatric
disorders including major depressive disorder, bipolar
disorder, schizophrenia, autism spectrum disorders, and
ADHD, and using a goodness-of-ﬁt model-selection pro-
cedure (Cross-Disorder Group of the Psychiatric Genom-
ics Consortium 2013). Findings suggest the potential for
shared genetics between these psychiatric disorders. How-
ever, because the heritability estimate of depression alone
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ity loci are expected to be challenging. Moreover, associa-
tions derived from twin studies include heritability
directly attributable to genes and to gene by shared
environment interactions. As a result, inability to identify
relevant environments and gene–environment interactions
is likely to reduce success when searching for depression
susceptible genes. It is further possible that relevant
genetic factors are due to private or rare mutations not
captured by GWAS chips or expression variations such as
epigenetics; this could also explain why our PS explained
little variation in the depression phenotype.
Consistent with previous research, our ﬁndings sug-
gest each common genetic variant of depression has a
very small effect and therefore is difﬁcult to detect. We
anticipated that the aggregate risk combining informa-
tion on multiple loci would strengthen our explanatory
capacity. This was supported in that the PS signiﬁcantly
predicted long-term average depression score, but the
improvement was an order of magnitude smaller than
necessary to explain the missing heritability. The limited
explanatory power of the genome-wide PS should be
interpreted cautiously because such agnostic PS are
likely composed primarily of false positives. Thus, the
genome-wide PS may include a few true causal loci
plus thousands of unrelated loci; adding substantial
noise to any causal variable will inevitably reduce its
correlation with the outcome. The explanatory power of
Table 3. Meta-analysis of percentage of variance explained in depression phenotype in NHS by the genome-wide agnostic polygenic scores in the
leave-one-substudy-out analysis (N = 6989).
Cumulative P-value thresholds for selecting SNPs Nonoverlapping P-value thresholds for selecting SNPs
Ptraining
1 threshold Percentage of variance explained P-value Ptraining
1 threshold Percentage of variance explained P-value
p<0.00001 0.1 0.355 0–0.00001 0.1 0.355
p<0.0001 0 0.528 0.00001–0.0001 0 0.944
p<0.001 0.2 0.159 0.0001–0.001 0.2 0.118
p<0.01 0.1 0.524 0.001–0.01 0.1 0.977
p<0.1 0.1 0.043 0.01–0.1 0.1 0.013
p<0.2 0.1 0.002 0.1–0.2 0.1 0.003
p<0.3 0.2 0.003 0.2–0.3 0.1 0.832
p<0.4 0.1 0.002 0.3–0.4 0.1 0.269
p<0.5 0.1 0.004 0.4–0.5 0 0.996
NHS, Nurses’ Health Study; SNP, single-nucleotide polymorphism.
1
Training set: remaining three NHS substudies except the testing sample.
Table 2. Meta-analysis GWAS results of 14-year long-term average composite depression measure of top ﬁndings (P < 10
 5) in four NHS sub-
studies (N = 6989).
SNP Chr Position
Allele 1/
Allele 2
Allele 1
frequency Closest gene
Approx.
distance (kb) Effect
Standard
error P-value
rs6763048 3 38656398 A/G 0.858 SCN5A Intron  0.076 0.016 8.42E-07
rs9323902
1 14 93641863 T/G 0.257 IFI27L1 3  0.063 0.013 2.43E-06
rs10873447
1 14 93642502 A/T 0.748 IFI27L1 3.6 0.063 0.014 2.71E-06
rs4366580 13 22333062 T/C 0.200 IPMKP1 23  0.062 0.013 3.90E-06
rs10512653 5 36474011 T/C 0.150 RANBP3L 136 0.069 0.015 4.08E-06
rs252928
2 5 5564990 A/G 0.345 KIAA0947 21 0.052 0.011 4.43E-06
rs17287770 3 46629429 C/G 0.928 LOC100132146  0.096 0.021 5.69E-06
rs2619855
2 5 5557842 T/C 0.653 KIAA0947 14  0.051 0.011 7.40E-06
rs4266492 6 40803132 A/C 0.950 LRFN2 139 0.137 0.031 7.56E-06
rs7182961 15 60707884 C/G 0.749 TLN2 19 0.057 0.013 7.70E-06
rs252930
2 5 5562703 A/C 0.339 KIAA0947 19 0.051 0.011 8.15E-06
rs252929
2 5 5563450 T/C 0.339 KIAA0947 20 0.051 0.011 9.13E-06
rs2652715
2 5 5567517 A/G 0.659 KIAA0947 24  0.051 0.011 9.16E-06
rs2578514
2 5 5574830 A/G 0.651 KIAA0947 31  0.050 0.011 9.81E-06
GWAS, genome-wide association studies; NHS, Nurses’ Health Study; SNP, single-nucleotide polymorphism.
1SNPs in linkage disequilibrium with each other (r
2 > 0.8) on chromosome 14.
2
SNPs in linkage disequilibrium with each other (r2 > 0.8) on chromosome 5.
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sample sizes, as the ratio of true to false positives
improves.
We also improved on prior GWA studies by using a
dimensional phenotype summarizing depressive symptoms
over 14 years. The literature suggests the etiology of
depression involves multiple genes each with small effect,
thus the relevant phenotype is likely to be normally
distributed. In addition, the long-term average score is
enhanced by virtue of having both valid symptom
measures (Radloff 1977; Silveira et al. 2005) and direct
information about depression diagnoses. This phenotype
should be less inﬂuenced by transient environmental fac-
tors and therefore more strongly related to stable genetic
predispositions. The enhanced phenotype was not strongly
predicted by the PS, however, suggesting the use of cross-
sectional depression phenotypes is not the critical barrier
to identifying genetic determinants. On the other hand, as
depression is suspected to be a heterogeneous phenotype,
in which individual patients may have a wide range of
clinical manifestations and simultaneously develop comor-
bid disorders, identifying a depression-related phenotype
which captures more homogeneous clinical features may
be critical for identifying the underlying genetic architec-
ture. Prior research has attempted to index plausible
sources of phenotypic heterogeneity in the depression
cases by stratifying analyses by gender, recurrence, age of
onset, or typicality, but such efforts have not yielded sta-
tistically signiﬁcant ﬁndings. This study only included
female subjects, and incorporated depression-related phe-
notype information collected multiple times across
14 years; as a result our phenotype may capture a more
chronic attribute or experience. However, age of onset was
not available in this study and the cases had a mixture of
symptom severity. The possible phenotypic heterogeneity,
if likely linked to genetic heterogeneity, could reduce sta-
tistical power to detect association signals.
We found heterogeneous PS effects across quantiles of
depression, consistent with the hypothesis that some loci
have worse effects on individuals with other types of
environmental or genetic vulnerability (Williams 2012).
Because we use a genome-wide PS, environmental factors
such as adverse life events or lack of social support seem
most likely. The larger effect of PS on high- versus low-
depression quantiles may support the hypothesis that the
“missing heritability” is attributable to epistatic or envi-
ronmental interactions, such that some genotypes are
relevant only in the context of other risk factors. Nearly
all twin studies rely on twins raised together; in such
studies, the variance attributable to shared environmental
factors modifying genetic effects is implicitly included in
heritability estimates (Kamin and Goldberger 2002). Gatz
et al. (1992) found little additive genetic variance among
twin pairs reared apart, suggesting the likely importance
of environment and gene–environment interactions.
Alternatively, heterogeneous PS effects across quantiles of
Table 4. Meta-analysis of percentage of variance explained in depres-
sion phenotype in NHS by the genetic risk scores using external GAIN-
MDD sample as the training set (N = 6989).
Outcome in NHS testing set
Continuous
depression score
Dichotomous
depression status
Ptraining threshold R
2%
1 P-value
1 R
2%
1,2 P-value
1
p<0.00001 —— — —
p<0.0001 0.1 0.807 0.1 0.697
p<0.001 0.1 0.203 0.2 0.450
p<0.01 0 0.866 0 0.775
p<0.1 0 0.922 0.1 0.520
p<0.2 0 0.581 0 0.863
p<0.3 0 0.394 0.1 0.903
p<0.4 0 0.300 0.1 0.651
p<0.5 0.1 0.344 0.1 0.653
GWAS, genome-wide association studies; GAIN-MDD, Genetic Associ-
ation Information Network—Major Depressive Disorder; NHS, Nurses’
Health Study.
1Use the GWAS result from GAIN-MDD as the training set, and use
each of the four NHS substudies as the testing set on recurrent com-
posite depression score. The ﬁnal weighted R
2 and P-value calculated
meta-analytically across four NHS substudies.
2Denotes Nagelkerke’s R
2%.
Table 5. Meta-analysis of percentage of variance explained in depres-
sion symptoms in NHS by the genetic risk scores using external PGC-
MDD sample as the training set (N = 6989).
Outcome in NHS testing set
Continuous
depression score
Dichotomous
depression status
Ptraining threshold R
2%
1 P-value
1 R
2%
1,2 P-value
1
p<0.00001 0 0.445 0.1 0.951
p<0.0001 0.1 0.192 0.1 0.309
p<0.001 0 0.644 0.1 0.291
p<0.01 0 0.240 0 0.639
p<0.1 0.1 0.078 0.1 0.309
p<0.2 0.1 0.030 0.1 0.263
p<0.3 0.1 0.049 0.1 0.46
p<0.4 0.1 0.041 0.1 0.415
p<0.5 0.1 0.031 0.1 0.313
GWAS, genome-wide association studies; PGC-MDD, Psychiatric
GWAS Consortium—Major Depressive Disorder; NHS, Nurses’ Health
Study.
1Use the nine-study meta-analyzed GWAS result from PGC-MDD as the
training set, and use each of the four NHS substudies as the testing set
on long-term composite depression score. The ﬁnal weighted R
2 and P-
value calculated meta-analytically across four NHS substudies.
2Denotes Nagelkerke’s R
2%.
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Figure 4. Quantile plot of polygenic scores (PS) on 14-year long-term average composite depression phenotype.
ª 2014 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. 307
S.-C. Chang et al. Polygenic Scores of Depressive Symptomsthe phenotype might represent noninterval scaling of the
phenotype or modeling error. Regardless of whether the
result is interpreted as evidence for gene–environment
interactions, the ﬁnding of heterogeneous effect sizes indi-
cates that mean effects estimated in linear regression
model may understate the overall impact of genetic risk.
Potential limitations of our study include generalizabil-
ity of the NHS blood sample, imprecision in depression
assessment, and different GWA platforms available in
each subcohort. Combing multiple GWAS results across
cohorts with different genotyping platforms and QC ﬁl-
ters is now common when studying the genetics of com-
plex diseases such as depression and schizophrenia,
because large sample sizes are necessary (Schizophrenia
Psychiatric Genome-Wide Association Study Consortium
2011; Hek et al. 2013). The QC has been carefully and
extensively examined internally, and the allele frequencies
are similar across NHS subcohorts.
In summary, combining longitudinal phenotype assess-
ments from multiple measurements and different poly-
genic scoring approaches did not substantially improve
genetic prediction of depression. Common SNPs
explained 0.2% or less of depression variance via poly-
genic scoring analysis. Many studies now suggest depres-
sion does not result from either purely genetic or
environmental inﬂuences, but rather from the intersection
of the two (Dunn et al. 2011). Because both components
are intertwined, the underlying association could be
obscured if either factor is neglected, especially when the
environments differ widely between samples. Identifying
social or environmental modiﬁers of genetic risks is a
critical next step to understand depression etiology.
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Appendix 1
Nested Genetic Case–Control Studies in NHS
Participants for the current analyses were from four inde-
pendent GWAS nested in the NHS initially designed to
study outcomes of breast cancer (BrCa, N = 2280), coro-
nary heart disease (CHD, N = 1135), type 2 diabetes
(T2D, N = 3084), and kidney stone (KS, N = 490) dis-
ease. Both cases and controls in each original GWAS were
included for analysis.
Brieﬂy, for the NHS BrCa study, cases and controls were
limited to postmenopausal women. Controls were matched
with cases by age and postmenopausal hormone use at
blood draw. For the NHS CHD study, controls were ran-
domly selected from the subcohort who provided blood
samples and did not experience CHD with two controls for
each case, matched with cases by age, smoking, and month
of blood draw. For the NHS T2D study, controls who were
deﬁned to be those free of diabetes at the time the case was
reported were matched on year of birth, month of blood
collection, and fasting status. For the NHS KS study, partic-
ipants with a history of kidney stones were matched to ran-
domly selected controls identiﬁed in two cycles from those
with no history of cancer (cycles 1 and 2) or cardiovascular
disease (cycle 1) who met age eligibility requirements (cycle
1: <66; cycle 2: <76). A total of 2280 women from the NHS
BrCa substudy, 1135 women from the CHD substudy, 3084
women from the T2D, and 490 women in the KS substudy,
all unrelated and genetically deﬁned whites who had non-
missing phenotype and covariate data, were included in this
study (total N = 6989).
Appendix 2
Construction of a 14-Year Long-Term
Average Depression Measure
The Nurses’ Health Study (NHS) began collecting depres-
sion-related measures starting in 1992. Information on
clinical and subclinical levels of depression has been
assessed with a variety of measures across seven subsequent
interview waves. For example, information on clinician-
diagnosed depression has been assessed every 2 years since
2000, and information on antidepressant use has been col-
lected every 2 years since 1996. Questionnaire-based mea-
sures with relevant symptom items were also administered,
including the SF-36, Center for Epidemiologic Studies
Depression Scale—10 items (CESD-10), life orientation
test, and geriatric depression scale—15 items (GDS-15).
These have been assessed either once or at multiple points
(Table S1). For the construction of a 14-year long-term
average phenotype, all assessments were scaled against a
common anchor score to make it possible to combine mea-
sures across waves. The GDS, assessed in 2008, has excellent
psychometric characteristics within the age span of our
population, has good validity as a continuous dimensional
measure of depressive symptomology, and good sensitivity
and speciﬁcity for clinical depression when dichotomized
(Sheikh and Yesavage 1986). We therefore chose the GDS
as our “anchor” assessment and scaled all other assessments
against the GDS. We chose GDS-15 over CESD-10 because
it was speciﬁcally developed for use in geriatric population
(the mean age of NHS participants were both over 70 years
old when either instrument was examined), it contained
fewer somatic items. In cognitively intact patients older
than 65 years, the GDS screen is the preferred instrument
because the psychometric data on the CES-D are mixed in
this population (Sharp and Lipsky 2002). Although the
quality of the available measures used across waves differs,
our approach down-weights those instruments that do not
correspond well with the GDS. Our protocol was as follows:
using all NHS women with GDS scores (regardless of the
availability of genetic data), we regressed the GDS score on
all depression-related measures available in that wave, using
a linear regression model. For example, using all measures
of the depression phenotype available in 2004, we estimated
the following linear regression:
EðGDS2008Þ¼b0þb1 Diagnosis2004þb2 Meds2004
þb3 CESD-102004þb4
 LifeOrientation2004þb5
 Sad2PlusWeeks2004
(1)
On the basis of this linear regression, we predicted the
value that the GDS score would have taken if it has been
assessed in 2004. We estimated similar models for each
interview wave, 1992–2006. For instruments with missing
data on a few items, we used the average of nonmissing
items if at least half of the items were reported and a
missing indicator method for observations missing more
than half of the items.
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the initial models to predict the value of GDS for each par-
ticipant at each wave, had he or she been given the GDS. In
this way, all individual depression measures collected at
one wave were rescaled and translated to a single common
scale (GDS-standardized score) for each participant, and
these estimates could be obtained even for individuals who
did not complete the GDS in 2008. The ﬁnal phenotype
was the average of the rescaled depression scores from all
available questionnaire cycles (up to seven waves):
14-Year Long-Term Average Composite Depression
Phenotype ¼
 X 7
i¼1
½EðGDS 15Þjdepression measure
inwavei 
  
number of waves
(2)
This approach maximized the available sample size
and optimized the information available on lifetime
experiences of depression, because anyone with at least
one wave of information with depression assessment
was included. We also believe it decreased the transient
component of the measure compared to using a single-
wave assessment, which would strengthen our ability to
detect genetic predictors. In fact, in our analytic sample
132 (1.9%) women had only one measure of depres-
sion, 136 (1.9%) had two measures, and 6721 (96.2%)
had three or more measures, in which 5256 (78%) had
complete data collection of depression measures in all
waves.
We assessed reliability and validity of the 14-year
long-term average composite depression phenotype in
the full NHS sample. First, we examined the correlation
of the standardized measures across waves with a com-
monly used measure of depressive symptoms, the
CESD-10 assessed at a single-wave in 2004. For the
73,897 women with both CESD-10 and the 14-year
average depression measure, the Pearson correlation
coefﬁcient was 0.74. This high but not perfect correla-
tion suggests that the 14-year average phenotype may
have more information in it. We assessed construct
validity by examining the association between the 14-
year composite measure and established correlates of
depression: cigarette smoking (pack-years) and physical
activity (Mets per week), assessed by self-report in
2004; paternal occupation when participants were
16 years old in 1976, husband’s education as a measure
of socioeconomic status assessed in 1992, and the aver-
age of phobic anxiety scale of the Crown Crisp Experi-
mental Index (CCI) between 1988 and 2004. We
expected the new 14-year average depression score to
be associated with greater likelihood of smoking, less
physical activity, and lower occupational and socioeco-
nomic status (Table 1). We also anticipated that 14-year
average depression would be more correlated with these
factors than a depressive symptom measure at any sin-
gle time point.
The mean (SD) of the new 14-year average composite
depression score in women with depression deﬁned by
CESD-10 was 2.68 (0.68), signiﬁcantly higher than those
without elevated CESD-10 scores (mean = 1.66,
SD = 0.47, t-test P-value <0.0001). As expected, cigarette
smoking, physical activity, and household characteristics
including husband’s highest education and paternal occu-
pation when participants were 16 years old, and phobic
anxiety scale in CCI all explained slightly more variance
in our 14-year average depression score than they
explained for the 2004 CESD-10 score (Table S4). This
result again suggests that the 14-year average depression
measure captures more information about a stable pheno-
type than the single-wave measure alone.
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